This is an oral medication in capsule form.
Dimethyl Fumarate Delayed-Release Capsules is an FDA-approved therapeutic equivalent to Tecfidera® (dimethyl fumarate). Dimethyl fumarate is a formulation that was developed specifically for use by people with multiple sclerosis. A chemically related compound, called Fumaderm (dimethyl fumarate and fumaric acid esters), has been used at higher doses for decades in Germany to treat acute flare-ups of psoriasis. Although its exact mechanism of action is not known, dimethyl fumarate is thought to modulate the immune response to be less inflammatory and may have antioxidant properties that could be protective against damage to the brain and spinal cord.
Dimethyl Fumarate Delayed-Release Capsules is approved by the FDA for the treatment of relapsing forms of multiple sclerosis to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease in adults.
Read the Society's news bulletin on the FDA approval of Dimethyl Fumarate Delayed Release Capsules here
to read the Dimethyl Fumarate Delayed-Release Capsules Prescribing Information for healthcare professionals (information for patients is at the end of this document).
Financial Assistance Program
No patient assistance program available at this time.